))
Season 2 - Episode 9: Management of cardiac amyloidosis - e-cigarettes and cardiovascular disease
Manage episode 407315167 series 3559418
Contenu fourni par European Society of Cardiology. Tout le contenu du podcast, y compris les épisodes, les graphiques et les descriptions de podcast, est téléchargé et fourni directement par European Society of Cardiology ou son partenaire de plateforme de podcast. Si vous pensez que quelqu'un utilise votre œuvre protégée sans votre autorisation, vous pouvez suivre le processus décrit ici https://fr.player.fm/legal.
ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly.
This episode covers:
- Cardiology This Week: A concise summary of recent studies
- Management of cardiac amyloidosis
- e-cigarettes and cardiovascular disease
- Statistics Made Easy: The Hazard Ratio
Host: Susanna Price
Guests: Carlos Aguiar, Julian Gillmore, Maryam Kavousi
Want to watch that episode? Go to: https://esc365.escardio.org/event/1144
Disclaimer
This programme is intended for health care professionals only and is to be used for educational purposes.
The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices.
Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.
Declarations of interests
Stephan Achenbach, Maryam Kavousi, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report.
Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, Lilly, Novartis, Pfizer, Sanofi, Servier, Tecnimede.
Davide Capodanno has declared to have potential conflicts of interest to report: Sanofi, Novo Nordisk, Terumo, Medtronic.
Julian Gillmore has declared to have potential conflicts of interest to report: consultancy for Alnylam, ATTRalus, AstraZeneca, Bridgebio, Intellia, Ionis, Lycia.
Emma Svennberg has declared to have potential conflicts of interest to report: institutional research grants from Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Boehringer-Ingelheim, Johnson & Johnson, Merck Sharp & Dohme.
42 episodes
Partager
